IDH1 and IDH2
Purpose
Activating IDH1 R132 and IDH2 R140 and R172 mutations are seen in gliomas, acute myeloid leukemias, cholangiocarcinomas, and a subset of cartilaginous tumors. In gliomas they are seen in a substantial proportion of low grade tumors; in acute myeloid leukemias they may identify tumors with a poor prognosis. In addition, targeted treatment is being developed for these mutations, which result in altered enzyme activity.
CPT Codes
81479, 88381
Methodology
Next generation sequencing (NGS) of DNA
Turnaround Time
14 days
Sample Tested
Parrafin embedded tissue (see requisition for detailed specimen requirements), whole blood or bone marrow aspirate in EDTA